Cargando…
Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1
BACKGROUND: The mechanisms underlying lesions of dopaminergic (DA) neurons, an essential pathology of Parkinson’s disease (PD), are largely unknown, although oxidative stress is recognized as a key factor. We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in PD p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080346/ https://www.ncbi.nlm.nih.gov/pubmed/33910636 http://dx.doi.org/10.1186/s40035-021-00239-0 |
_version_ | 1783685405131931648 |
---|---|
author | Shi, Liangqin Lin, Yazhou Jiao, Yucheng Herr, Seth A. Tang, Jonathan Rogers, Edmond Chen, Zhengli Shi, Riyi |
author_facet | Shi, Liangqin Lin, Yazhou Jiao, Yucheng Herr, Seth A. Tang, Jonathan Rogers, Edmond Chen, Zhengli Shi, Riyi |
author_sort | Shi, Liangqin |
collection | PubMed |
description | BACKGROUND: The mechanisms underlying lesions of dopaminergic (DA) neurons, an essential pathology of Parkinson’s disease (PD), are largely unknown, although oxidative stress is recognized as a key factor. We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in PD pathology, and that acrolein scavenger hydralazine can reduce the elevated acrolein, mitigate DA neuron death, and alleviate motor deficits in a 6-hydroxydopamine (6-OHDA) rat model. As such, we hypothesize that a structurally distinct acrolein scavenger, dimercaprol (DP), can also offer neuroprotection and behavioral benefits. METHODS: DP was used to lower the elevated levels of acrolein in the basal ganglia of 6-OHDA rats. The acrolein levels and related pathologies were measured by immunohistochemistry. Locomotor and behavioral effects of 6-OHDA injections and DP treatment were examined using the open field test and rotarod test. Pain was assessed using mechanical allodynia, cold hypersensitivity, and plantar tests. Finally, the effects of DP were assessed in vitro on SK-N-SH dopaminergic cells exposed to acrolein. RESULTS: DP reduced acrolein and reversed the upregulation of pain-sensing transient receptor potential ankyrin 1 (TRPA1) channels in the substantia nigra, striatum, and cortex. DP also mitigated both motor and sensory deficits typical of PD. In addition, DP lowered acrolein and protected DA-like cells in vitro. Acrolein’s ability to upregulate TRPA1 was also verified in vitro using cell lines. CONCLUSIONS: These results further elucidated the acrolein-mediated pathogenesis and reinforced the critical role of acrolein in PD while providing strong arguments for anti-acrolein treatments as a novel and feasible strategy to combat neurodegeneration in PD. Considering the extensive involvement of acrolein in various nervous system illnesses and beyond, anti-acrolein strategies may have wide applications and broad impacts on human health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-021-00239-0. |
format | Online Article Text |
id | pubmed-8080346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80803462021-04-29 Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 Shi, Liangqin Lin, Yazhou Jiao, Yucheng Herr, Seth A. Tang, Jonathan Rogers, Edmond Chen, Zhengli Shi, Riyi Transl Neurodegener Research BACKGROUND: The mechanisms underlying lesions of dopaminergic (DA) neurons, an essential pathology of Parkinson’s disease (PD), are largely unknown, although oxidative stress is recognized as a key factor. We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in PD pathology, and that acrolein scavenger hydralazine can reduce the elevated acrolein, mitigate DA neuron death, and alleviate motor deficits in a 6-hydroxydopamine (6-OHDA) rat model. As such, we hypothesize that a structurally distinct acrolein scavenger, dimercaprol (DP), can also offer neuroprotection and behavioral benefits. METHODS: DP was used to lower the elevated levels of acrolein in the basal ganglia of 6-OHDA rats. The acrolein levels and related pathologies were measured by immunohistochemistry. Locomotor and behavioral effects of 6-OHDA injections and DP treatment were examined using the open field test and rotarod test. Pain was assessed using mechanical allodynia, cold hypersensitivity, and plantar tests. Finally, the effects of DP were assessed in vitro on SK-N-SH dopaminergic cells exposed to acrolein. RESULTS: DP reduced acrolein and reversed the upregulation of pain-sensing transient receptor potential ankyrin 1 (TRPA1) channels in the substantia nigra, striatum, and cortex. DP also mitigated both motor and sensory deficits typical of PD. In addition, DP lowered acrolein and protected DA-like cells in vitro. Acrolein’s ability to upregulate TRPA1 was also verified in vitro using cell lines. CONCLUSIONS: These results further elucidated the acrolein-mediated pathogenesis and reinforced the critical role of acrolein in PD while providing strong arguments for anti-acrolein treatments as a novel and feasible strategy to combat neurodegeneration in PD. Considering the extensive involvement of acrolein in various nervous system illnesses and beyond, anti-acrolein strategies may have wide applications and broad impacts on human health. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-021-00239-0. BioMed Central 2021-04-28 /pmc/articles/PMC8080346/ /pubmed/33910636 http://dx.doi.org/10.1186/s40035-021-00239-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Shi, Liangqin Lin, Yazhou Jiao, Yucheng Herr, Seth A. Tang, Jonathan Rogers, Edmond Chen, Zhengli Shi, Riyi Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 |
title | Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 |
title_full | Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 |
title_fullStr | Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 |
title_full_unstemmed | Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 |
title_short | Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1 |
title_sort | acrolein scavenger dimercaprol offers neuroprotection in an animal model of parkinson’s disease: implication of acrolein and trpa1 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080346/ https://www.ncbi.nlm.nih.gov/pubmed/33910636 http://dx.doi.org/10.1186/s40035-021-00239-0 |
work_keys_str_mv | AT shiliangqin acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT linyazhou acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT jiaoyucheng acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT herrsetha acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT tangjonathan acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT rogersedmond acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT chenzhengli acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 AT shiriyi acroleinscavengerdimercaproloffersneuroprotectioninananimalmodelofparkinsonsdiseaseimplicationofacroleinandtrpa1 |